HLB Panagene to Deliver Opening Keynote at U.S. Oligonucleotide and Peptide Conference

HLB Panagene will deliver the opening keynote presentation on its proprietary material, peptide nucleic acid (PNA), at the "Oligonucleotides & Peptides Xchange - San Francisco 2026," which will be held in San Francisco, USA next month.

Opening keynote presentation of HLB Panagen introduced on the official website of the organizer, Hub Xchange. HLB Panagen

According to HLB Panagene on August 12, ONP San Francisco is a specialized conference where drug development experts and key decision-makers from global pharmaceutical and biotechnology companies participate to discuss the latest technologies and business collaboration opportunities in the fields of oligonucleotide and peptide therapeutics. The event centers around senior-level researchers from companies with new drug pipelines, featuring keynote presentations, expert roundtable discussions, and one-on-one meetings between companies, covering main topics such as next-generation drug modalities, drug delivery, CMC and process development, and quality management.

This keynote presentation will focus on highlighting the differentiated characteristics and competitive advantages of PNA, which has recently regained attention in the oligonucleotide therapeutics sector. The presentation will examine the technical strengths of PNA compared to existing oligonucleotides, explore reasons for its previously limited application, and introduce verified case studies of its application in various fields including cell and gene therapy (CGT), as well as discuss its potential for expansion as a new drug development platform.

In particular, this presentation has been arranged through collaboration with ChemGenes, HLB Panagene's US distribution partner for PNA. HLB Panagene currently supplies PNA products throughout the United States via ChemGenes, and plans to actively promote the potential of PNA for new drug development, expand touchpoints with local research institutions and pharmaceutical and biotechnology companies, and accelerate the global expansion of its PNA business.

Jang Ingeun, CEO of HLB Panagene, said, "PNA is a material offering great potential for use in various drug development sectors due to its unique properties, such as high binding affinity and stability. Through this presentation, we will actively promote the competitiveness of PNA to global drug development companies and researchers, and continue to expand R&D collaborations and business opportunities in the United States and other global markets."

This content was produced with the assistance of AI translation services.